Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GNPX 
Genprex Inc (GNPX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: GNPX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.5
1 Year Target Price $7.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.55% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.76M USD | Price to earnings Ratio 0.34 | 1Y Target Price 7.5 |
Price to earnings Ratio 0.34 | 1Y Target Price 7.5 | ||
Volume (30-day avg) 1 | Beta -0.64 | 52 Weeks Range 0.14 - 3.97 | Updated Date 09/14/2025 |
52 Weeks Range 0.14 - 3.97 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.85 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -207.41% | Return on Equity (TTM) -612.3% |
Valuation
Trailing PE 0.34 | Forward PE - | Enterprise Value 8415416 | Price to Sales(TTM) - |
Enterprise Value 8415416 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.18 | Shares Outstanding 33466800 | Shares Floating 33361698 |
Shares Outstanding 33466800 | Shares Floating 33361698 | ||
Percent Insiders 0.33 | Percent Institutions 2.23 |
Upturn AI SWOT
Genprex Inc
Company Overview
History and Background
Genprex, Inc. is a clinical-stage gene therapy company founded in 2009. They focus on developing therapies for cancer and diabetes. The company has evolved from early-stage research to clinical trials, primarily focusing on their lead candidate, REQORSAu2122.
Core Business Areas
- Oncology: Developing gene therapies for various cancer types, with REQORSAu2122 as their primary focus.
- Diabetes: Developing gene therapies for diabetes, although oncology is currently their main focus.
Leadership and Structure
The leadership team consists of experienced executives in the biotechnology and pharmaceutical industries. The organizational structure is typical of a small, clinical-stage biotech company, with functional departments supporting research, development, and operations.
Top Products and Market Share
Key Offerings
- REQORSAu2122 (quaratusugene ozeplasmid): Genprex's lead product candidate, a gene therapy being developed for non-small cell lung cancer (NSCLC). Market share data is unavailable as the product is still in clinical trials and has not yet received FDA approval. Key competitors include existing treatments for NSCLC such as chemotherapy, immunotherapy (e.g., Keytruda from Merck), and targeted therapies (e.g., Tagrisso from AstraZeneca).
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by advancements in technology and increasing success in clinical trials. The oncology segment of this market is particularly attractive due to the high unmet need for effective cancer treatments.
Positioning
Genprex is positioned as a clinical-stage gene therapy company targeting NSCLC. Their competitive advantage lies in their unique approach to gene therapy and their focus on a specific patient population. The unmet need for novel therapies in cancer provides significant opportunity.
Total Addressable Market (TAM)
The global non-small cell lung cancer (NSCLC) therapeutics market is projected to reach billions of dollars annually. Genprex is positioned to capture a portion of this TAM if REQORSAu2122 proves to be effective and receives regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel gene therapy approach
- Focus on unmet medical needs in oncology
- Experienced management team
- Potential for breakthrough therapy designation
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Lack of commercialized products
- Small market capitalization
Opportunities
- Successful clinical trial results leading to FDA approval
- Partnerships with larger pharmaceutical companies
- Expansion into other cancer indications
- Advancements in gene therapy technology
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- MRK
- AZN
- BMY
- LLY
Competitive Landscape
Genprex faces significant competition from established pharmaceutical companies with approved NSCLC therapies. Genprex's competitive advantage lies in its novel gene therapy approach, but it must demonstrate clinical efficacy and safety to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by research and development activities and clinical trial progress.
Future Projections: Future growth is highly dependent on the success of REQORSAu2122 in clinical trials and potential regulatory approval. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing REQORSAu2122 through clinical trials, exploring partnerships, and securing additional funding.
Summary
Genprex is a clinical-stage gene therapy company focusing on oncology and diabetes. The company's lead product, REQORSAu2122, is currently in clinical trials for NSCLC. Its success hinges on positive clinical trial outcomes and regulatory approval. They need to secure partnerships and additional funding, while also addressing the risks associated with clinical trials and market competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
- Various Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market information are subject to change. The AI-based rating is based on a limited set of publicly available information and should be interpreted with caution. Market share for GNPX is minimal because they do not have approved therapy yet.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Genprex Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2018-03-29 | President, CEO, CFO & Director Mr. Ryan M. Confer M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | Website https://www.genprex.com |
Full time employees 15 | Website https://www.genprex.com | ||
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.